BioCentury
ARTICLE | Company News

2-BBB, Oncology Venture deal

March 31, 2017 7:46 PM UTC

2-BBB granted Oncology Venture exclusive, worldwide rights to develop and commercialize 2X-111 (formerly 2B3-101) to treat cancer. The pegylated liposomal doxorubicin conjugated with glutathione has c...

BCIQ Company Profiles

Allarity Therapeutics Inc.